Background: Vertebral fractures (VFs) are a frequent complication of acromegaly, but no studies have been so far published on effectiveness of antiosteoporotic drugs in this clinical setting. Objective: To evaluate whether in real-life clinical practice bone active drugs may reduce the risk of VFs in patients with active or controlled acromegaly. Study design: Retrospective, longitudinal study including 9 tertiary care endocrine units. Patients and methods: Two hundred and forty-eight patients with acromegaly (104 males; mean age 56.00 ± 13.60 years) were evaluated for prevalent and incident VFs by quantitative morphometric approach. Bone active agents were used in 52 patients (20.97%) and the median period of follow-up was 48 months (range 12-132). Results: During the follow-up, 65 patients (26.21%) developed incident VFs in relationship with pre-existing VFs (odds ratio [OR] 3.75; P < .001), duration of active acromegaly (OR 1.01; P = .04), active acromegaly at the study entry (OR 2.48; P = .007), and treated hypoadrenalism (OR 2.50; P = .005). In the entire population, treatment with bone active drugs did not have a significant effect on incident VFs (P = .82). However, in a sensitive analysis restricted to patients with active acromegaly at study entry (111 cases), treatment with bone active drugs was associated with a lower risk of incident VFs (OR 0.11; P = .004), independently of prevalent VFs (OR 7.65; P < .001) and treated hypoadrenalism (OR 3.86; P = .007). Conclusions: Bone active drugs may prevent VFs in patients with active acromegaly.

Mazziotti, G., Battista, C., Maffezzoni, F., Chiloiro, S., Ferrante, E., Prencipe, N., Grasso, L., Gatto, F., Olivetti, R., Arosio, M., Barale, M., Bianchi, A., Cellini, M., Chiodini, I., De Marinis Grasso, L., Del Sindaco, G., Di Somma, C., Ferlin, A., Ghigo, E., Giampietro, A., Grottoli, S., Lavezzi, E., Mantovani, G., Morenghi, E., Pivonello, R., Porcelli, T., Procopio, M., Pugliese, F., Scillitani, A., Lania, A., Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study, <<THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM>>, 2020; (105): 3285-3292 [http://hdl.handle.net/10807/188265]

Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study

Chiloiro, S;Bianchi, A;De Marinis Grasso, Laura;Giampietro, A;
2020

Abstract

Background: Vertebral fractures (VFs) are a frequent complication of acromegaly, but no studies have been so far published on effectiveness of antiosteoporotic drugs in this clinical setting. Objective: To evaluate whether in real-life clinical practice bone active drugs may reduce the risk of VFs in patients with active or controlled acromegaly. Study design: Retrospective, longitudinal study including 9 tertiary care endocrine units. Patients and methods: Two hundred and forty-eight patients with acromegaly (104 males; mean age 56.00 ± 13.60 years) were evaluated for prevalent and incident VFs by quantitative morphometric approach. Bone active agents were used in 52 patients (20.97%) and the median period of follow-up was 48 months (range 12-132). Results: During the follow-up, 65 patients (26.21%) developed incident VFs in relationship with pre-existing VFs (odds ratio [OR] 3.75; P < .001), duration of active acromegaly (OR 1.01; P = .04), active acromegaly at the study entry (OR 2.48; P = .007), and treated hypoadrenalism (OR 2.50; P = .005). In the entire population, treatment with bone active drugs did not have a significant effect on incident VFs (P = .82). However, in a sensitive analysis restricted to patients with active acromegaly at study entry (111 cases), treatment with bone active drugs was associated with a lower risk of incident VFs (OR 0.11; P = .004), independently of prevalent VFs (OR 7.65; P < .001) and treated hypoadrenalism (OR 3.86; P = .007). Conclusions: Bone active drugs may prevent VFs in patients with active acromegaly.
Inglese
Mazziotti, G., Battista, C., Maffezzoni, F., Chiloiro, S., Ferrante, E., Prencipe, N., Grasso, L., Gatto, F., Olivetti, R., Arosio, M., Barale, M., Bianchi, A., Cellini, M., Chiodini, I., De Marinis Grasso, L., Del Sindaco, G., Di Somma, C., Ferlin, A., Ghigo, E., Giampietro, A., Grottoli, S., Lavezzi, E., Mantovani, G., Morenghi, E., Pivonello, R., Porcelli, T., Procopio, M., Pugliese, F., Scillitani, A., Lania, A., Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study, <<THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM>>, 2020; (105): 3285-3292 [http://hdl.handle.net/10807/188265]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/188265
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 6
social impact